Starling Oncology, Inc. STLN
$6.93
$0.304.45%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 161.28M | 147.44M | 141.96M | 136.56M | 119.80M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 161.28M | 147.44M | 141.96M | 136.56M | 119.80M |
| Cost of Revenue | 134.12M | 124.13M | 119.19M | 117.64M | 102.30M |
| Gross Profit | 27.17M | 23.32M | 22.77M | 18.92M | 17.50M |
| SG&A Expenses | 29.94M | 28.21M | 28.04M | 25.25M | 26.91M |
| Depreciation & Amortization | 1.84M | 1.62M | 1.63M | 1.72M | 1.81M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 165.90M | 153.95M | 148.86M | 144.62M | 131.01M |
| Operating Income | -4.62M | -6.51M | -6.91M | -8.05M | -11.21M |
| Income Before Tax | -9.79M | -2.49M | -7.51M | -16.50M | -17.14M |
| Income Tax Expenses | -- | -- | 0.00 | -- | -131.00K |
| Earnings from Continuing Operations | -9.79M | -2.49M | -7.51M | -16.50M | -17.01M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -9.79M | -2.49M | -7.51M | -16.50M | -17.01M |
| EBIT | -4.62M | -6.51M | -6.91M | -8.05M | -11.21M |
| EBITDA | -2.78M | -4.90M | -5.28M | -6.33M | -9.41M |
| EPS Basic | -0.08 | -0.02 | -0.06 | -0.14 | -0.15 |
| Normalized Basic EPS | -0.06 | -0.02 | -0.05 | -0.11 | -0.11 |
| EPS Diluted | -0.08 | -0.02 | -0.06 | -0.14 | -0.15 |
| Normalized Diluted EPS | -0.06 | -0.02 | -0.05 | -0.11 | -0.11 |
| Average Basic Shares Outstanding | 103.03M | 101.80M | 101.46M | 97.47M | 93.20M |
| Average Diluted Shares Outstanding | 103.03M | 101.80M | 101.46M | 97.47M | 93.20M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |